SOURCES SOUGHT
65 -- Safety IV Catheters
- Notice Date
- 9/15/2009
- Notice Type
- Sources Sought
- NAICS
- 339113
— Surgical Appliance and Supplies Manufacturing
- Contracting Office
- Department of the Air Force, Air Force Materiel Command, 88th Medical Group-Wright Patterson Medical Center, Bldg 830, 4881 Sugar Maple Dr, Wright-Patterson AFB, Ohio, 45433, United States
- ZIP Code
- 45433
- Solicitation Number
- R5-09-15-09-081-SIVC
- Archive Date
- 10/21/2009
- Point of Contact
- Phyllis A Targett, Phone: 937-257-9075, Keith Tousignant, Phone: 937-257-6398
- E-Mail Address
-
phyllis.targett@wpafb.af.mil, keith.tousignant@wpafb.af.mil
(phyllis.targett@wpafb.af.mil, keith.tousignant@wpafb.af.mil)
- Small Business Set-Aside
- N/A
- Description
- 65-Medical Supplies-Potential Sources Sought --------------- A. General Information The Heartland Region seeks approval to initiate the standardization process for Safety IV Catheters for its 7 Army, Navy, U.S. Coast Guard and US Air Force Medical Treatment Facilities (MTF's) in the states of Ohio, Illinois, Kentucky, Tennessee and Michigan in the Heartland Region including institutional and operational healthcare settings. Standardization action for this product line represents a new initiative. Vendors MUST provide a complete list of items supplied (catalog, etc.) and product literature in response to this Request for RIA Quotes (RFQ). Vendors are required to supply all items listed in all sizes and styles listed. Vendors who do not have a complete product line, as detailed in 1a of the Technical Criteria below, will be disqualified in Phase I. The primary objective of this program is to standardize the quality of care across this region based on a best value determination that represents the clinically preferred product or source(s) at the best possible price. It is also intended that standardized product be obtained through the DoD Prime Vendor (PV) Program. The seven facilities in the area include Wright Patterson Air Force Base Ohio, Scott Air Force Base Illinois, Naval Health Clinics of Great Lakes Illinois, Blanchfield Army Community Hospital Ft Campbell Kentucky, Ireland Army Community Hospital Ft Knox Kentucky, Naval Hospital Corps School Great Lakes Illinois, and USCG Air Station Traverse City Michigan. This standardization action is part of the Medical/Surgical PV program executed by the Defense Supply Center Philadelphia, Directorate of Medical Materiel. To participate, your company must have a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the Regions current PV Owens & Minor. This is pursuant to the DAPA clause by which DAPA holders agree to the Standardization process and to allow PV to distribute their products. This RFQ will result in Regional Incentive Agreements (RIAs) that supplement to the PV Program and it is not a contract. For additional information regarding DSCP's PV program please access their web site at https://dmmonline.dscp.dla.mil The resulting Regional Incentive Agreement (RIA) will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month option periods. Anticipated selection date is February 2010. The evaluation will be based on clinical, technical, and pricing factors. The Technical/Company and Clinical/Performance evaluation factors, when combined, are considered significantly more important than cost or price. As the technical and clinical evaluation results become more equal, price will become more important. The selection will be determined utilizing Best value/ trade-off criteria. The selection of a single vendor is anticipated. However, if no single vendor can meet the total requirement of the Region, the Government reserves the right to make two or more selections for RIAs. In this event, selection would be based on a combination of MTF preference and product availability. Point of Contact Phyllis Targett 937-257-9075 phyllis.targett@wpafb.af.mil B. Products and Performance Required The Heartland Region is seeking product line items in the category of Safety IV Catheters, which at a minimum includes the high volume lines below. Within this region, this product line has an estimated annual dollar requirement of $748,342.80. This forecast is based on historical CDMIA sales for a 12-month period. The top-ten (10) high volume usage lines for this project are shown in the Technical/Company Criteria below. At the request of the Heartland Region MTF's vendors will provide on-site support and in-servicing, educational resources and tools for clinical use of the product, conversion information, PV order numbers, MSDS information, and itemization of the brands, types and packaging information of the products provided by the vendor. C. Instructions to Vendors DAPA holders interested in participating in this standardization initiative should email their (1) Company name and address, (2) POC (Name and Phone Number, Fax Number, and E-mail address) to phyllis.targett@wpafb.af.mil (937) 257-9075. All e-mail communication between vendors and the Region must be digitally signed. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) must be digitally signed as well. Submissions must be received by 4:00 PM EST on the specified closing date of this RFQ. Vendors that fail to meet this submittal deadline will be disqualified from participating. This process will include vendor requirements for providing electronic responses to technical criteria, no charge literature for clinical evaluation, and submission of electronic best price quotes. Due to the potential for e-mail to be lost in transmission from network security, etc., vendors are strongly encouraged to confirm with the Regional POC stated above their initial submission, best price submissions, and literature or other requested information have actually arrived at the Heartland Region Tri-Service Business Office (TRBO) via e-mail. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date/time, should a problem occur with the first submission. D. Evaluation Criteria The Tri-Service Product Review Board (TPRB) is the governing body of the standardization process. This board includes clinicians and logisticians from all of the MTF's within the Heartland Region. They are the deciding officials for this initiative. The Heartland Region intends to evaluate price quotes and select a vendor or vendors without discussions. Vendor quotes should contain the vendor's best product matches for the products or product lines requested in this announcement. Vendor quotes should contain the vendor's best responses to all technical and/or company questions listed in this announcement. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Region). Additionally, the Heartland Region reserves the right to conduct discussions and request revised quotes, if it is determined to be necessary. If a down selection is made during the evaluation process, the Region may limit the number of quotes to the greatest number that will permit an efficient competition among vendors. Phase I-Technical/Company Evaluation Process Interested vendors are to respond to this FBO announcement by emailing their "intent to participate" to the above POC by the required response date. Based on vendor responses, the TRBO POC will request detailed responses to the technical/company criteria from each vendor. Vendors are required to meet/provide responses to the technical/company criteria stated below. All technical/company criteria are weighted equally. The responses will be reviewed under the purview of the TPRB by the Clinical Product Team (CPT), to determine the acceptability of each vendor. After the review of the technical/company criteria, those vendors who meet these criteria will qualify and be invited to participate in the clinical/performance evaluation. In general, "acceptability" for purposes of evaluation of technical/company criteria is defined as follows: (1) based on the vendor's responses, the evaluators have reasonable confidence that the line of products and/or services submitted meet the medical standards of care of the community, applicable to such products or services; (2) the vendor's information provided is factually correct. Any misrepresentation of information will disqualify the vendor from further consideration. NOTE: Specific technical/company criteria will require an additional, more-specific definition of "technical acceptability." The specific standard for technical acceptability will be set forth with the individual statement of each criterion, as required. All communications of significant milestones, such as invitations to participate, notices of disqualification, etc. must be digitally signed. Technical/Company Criteria: 1. Vendors must provide a complete line of Safety IV Catheters for single use. At a minimum, a complete product line includes: I.V. CATHETER, INSYTE AUTOGUARD, 18 GA X 1.16 IN., I.V. CATHETER, INSYTE AUTOGUARD, 22 GA X 1.0 IN., INTROCAN SAFETY-W FEP 18G, 1.3X32MM-US, PROTECTIV PLUS IV CATHETER OCR POLY/R-O, 18G X 1 1/4", ANGIOCATH IV CATHETER FOR SPECIAL PLACAEMENT PROCEDURES MADE OF FEP POLYMER 14GX1.88IN (2.1MMX48MM), PROTECTIV PLUS IV CATHETER OCR POLY/R-O, 20G X 1", ANGIOCATH IV CATHETER FOR SPECIAL PLACEMNET PROCEDURES FEP POLYMER 14G X 3.25IN (2.1MM X 83MM), I.V. CATHETER, INSYTE AUTOGUARD, 20 GA. X 1.16 IN,.PROTECTIV IV CATHETER PLASTIC HUB/R-O, 20G X 1 1/4", ANGIOCATH AUTOGUARD SHIELDED IV CATHETER MADE OF TEFLON 18G X 1.16IN. (1.3MM X 30MM). 2. Vendors must provide a complete list of items supplied (catalog, etc.) and product literature in response to this RFQ. Vendors are required to supply all items listed in all sizes. Vendors who do not have a complete product line as above will be disqualified in Phase I. 3. Vendors must have a DAPA or be in the process of applying for a DAPA number for the Safety IV Catheters product line. Provide the DAPA number or proof of the application process in response to this RFQ. (Note that vendors that fail to have a DAPA or show a lack of progress in obtaining a DAPA will be disqualified.) 4. Vendors must have a separate agreement with the current Prime Vendor for the Heartland Region, Owens & Minor, for distribution in the Heartland Region. (Note a vendor whose products are not available through the regional PV will be disqualified). 5. Please provide your 4 digit Prime Vendor Number, in response to this RFQ. If unknown, contact Owens and Minor. 6. Vendors must submit discounts off DAPA for all products included in this standardization initiative. Vendors that fail to submit a discount from DAPA will be disqualified. Where lower uncommitted FSS prices are available, DAPA holders are required by previous agreement to provide the uncommitted FSS price as the DAPA price. Vendors shall not quote uncommitted FSS prices as the discounted price for purposes of this standardization initiative. Vendors are to provide quote on discounts, in response to this RFQ. Vendors who do not provide discounts off DAPA for all products in this product line will be disqualified. 7. Vendors MUST provide any history of back orders and/or recalls that occurred during the most recent 12-month period for the Safety IV Catheters, including dates, duration, cause, and resolution. Vendors will not have an opportunity to provide additional information on back orders and recalls during any subsequent stage in this evaluation. Vendors are encouraged to submit all information deemed relevant (i.e., positive resolutions, etc.) in response to this RFQ. The Government will not contact any points of contact provided in response to this question. Vendors should not provide point of contact information in response to this question. 8. Vendors must provide a statement confirming their products meet the industry production and safety standards used in manufacturing IV Catheter products, in response to this RFQ. 9. Vendors must provide statement revealing all products containing synthesized polymer (plastic/rubber) are clearly labeled as latex free/safe, in response to this RFQ. 10. Vendors must provide documentation demonstrating the safety feature is an integral part of the intravenous catheter, in response to this RFQ 11. Vendors must provide documentation showing after activation of the safety feature it remains activated during disconnection of the needle from the catheter and after disposal, in response to this RFQ. 12. Vendors must provide documentation if your IV catheter's are incompatible with any intravenous fluids/medications, in response to this RFQ. 13. Vendors must provide a statement confirming products come capped and sterile in a 12 point font or better labeled package that can be delivered to a sterile field, in response to this RFQ. Phase II-Clinical/Performance Evaluation and Price Analysis Process: Upon completion of the Phase I - Technical/Company Criteria Evaluation, vendors who are selected to progress to clinical/performance evaluations will be requested to provide product samples concurrent with their best product and price discount quotes being requested. Clinical Evaluation Process: For those companies that meet the requirements above, the Clinical Product Team (CPT) will request samples from the product group to be clinically evaluated at select Military Treatment Facilities (MTFs). Vendors are required to ship samples direct to the MTFs. Vendor samples must be received no later than 4:00 P.M. (EST), fourteen (14) calendar days after the request for samples is issued to the vendors. Vendors failing to comply by the deadline will be disqualified from further consideration in the standardization process. All vendors must send the TRBO verification regarding the quantity, products, description of items, and date of shipment from the vendor, anticipated delivery date and individual who signed for literature and product sample sets. Specific MTFs will evaluate the vendor's product sample sets against the clinical/performance criteria in a clinical/patient care setting using a Likert-like scale, with a one to five rating. The scale descriptors are: 1 = strongly disagree, 2=disagree, 3=neutral, 4=agree and 5 = strongly agree. All clinical/performance criteria are weighted equally. The clinical/performance evaluation period will last for 21 calendar days. The CPT has established a target threshold of 3.00 for the Clinical Acceptability of products for standardization. The CPT will establish the "actual" clinical acceptability threshold following the clinical evaluation/data analysis. The CPT may consider how closely scores are clustered near the acceptability target threshold of 3.00 in determining the actual acceptability threshold that will allow a reasonable source selection decision. Vendors scoring below the actual acceptability threshold will be determined to be clinically unacceptable and disqualified from further consideration for this standardization initiative. Vendors that have been disqualified will be notified in writing at the conclusion of the evaluation process. During the pre-source selection procedures, the CPT validated/approved the equally weighted clinical/performance criteria outlined below. Clinical/Performance Criteria: 1. Packaging identifies the gauge and length of the catheter (safety in urgent- care setting. a. Reduces the amount of time needed for staff to select the appropriate size for patient care needs b. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 2. The catheter allows visualization of flashback (clinical efficiency) a. Allows additional confirmation clinician has entered the vein b. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 3. The catheter hub is Luer-Lock compatible to secure tubing (patient safety) a. Prevents tubing from accidental disconnects b. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 4. The catheter sheath moves freely on the needle to facilitate cannulation (patient comfort) a. Causes less manipulation at insertion site b. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 5. The safety feature is an integral part of the device, activates automatically and is not an accessory. (Clinician safety) a. Prevention of accidental needle stick b. OSHA prevention of Blood borne pathogen standard c. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 6. The safety feature allows or requires the workers hands to remain behind the needle at all times. (Clinician safety) a. Prevention of accidental needle stick b. OSHA prevention of Blood borne pathogen standard c. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 7. The safety feature is in effect before disassembly and remains in effect after disposal. (clinician safety) a. Prevention of accidental needle stick b. OSHA prevention of Blood borne pathogen standard c. This criterion will be evaluated by each clinician, in a clinical/patient care setting. 8. Patient does not perceive more pain or discomfort with this device. (clinician safety) a. No increase in pain b. Device should cause no more pain than currently used IV Catheter. c. This criterion will be evaluated by each clinician, in a clinical/patient care setting. Price Analysis Process: 1. Vendors will be given 14 calendar days from the date of pricing requests, to submit RIA pricing quotes, in a prescribed electronic spreadsheet format, based upon the requirements of the Heartland Region. Pricing must be received at the TRBO by 4:00 PM (EST), fourteen (14) calendar days after the issue date of the vendor notice to submit best product and price quotes. Failure to respond within this timeframe will result in your company being excluded from further participation/consideration The Region intends to evaluate quotes and select a vendor on initial submissions/quotes. Vendor quotes should contain the vendor's best product matches for the products or product lines requested in this announcement. Vendor quotes should also contain the vendor's best responses to any other technical and/or company questions listed in this request. Vendor quotes should contain the vendor's best tiered-pricing discounts off of the vendor's DAPA pricing (based on committed volume of 80% of the total requirements of the MTFs in the Region). 2. Vendors will forward pricing to the TRBO, and the TRBO will prepare a pricing analysis to be reviewed by the TPRB. Pricing will be based on a committed volume for a two-year period with the potential for three (3) one-year option periods (not to exceed 5 years). 3. The Technical/Company and Clinical/Performance evaluation factors, when combined, are considered significantly more important than cost or price. As the evaluation results become more technically and clinically equal, price will become more important. 4. The following elements may be considered in the pricing analysis: a. Impact of RIA prices on the Region (Post-Standardization Costs); b. Potential Cost Avoidance, (representing the discount offered by the company from their DAPA and FSS pricing with cost avoidance being the difference between DAPA pricing and RIA pricing multiplied by the number of items purchased over time). c. Impact of Unmatched Lines (i.e., do the unmatched lines make it difficult to compare the prices of the various vendors, because the evaluator cannot compare similar product lines for each vendor?); and d. Consideration of Stock Keeping Units (SKUs) by each vendor. The Region intends to reduce the number of SKUs that must be handled per period. Vendors that can supply the complete range of clinically-required product, without unnecessary numbers of SKUs for minimally-differentiated products, will be more likely to provide the best-value solution for the Government in this standardization initiative. The Region reserves the right to limit the number of quotes to the greatest number that will permit an efficient competition among vendors. The Region reserves the right to make a down-selection during the evaluation process based on considerations of efficient competition. Non-Selected Vendors will be notified in writing regarding selection/non-selection at the conclusion of the completed product evaluation process.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USAF/AFMC/74MG/R5-09-15-09-081-SIVC/listing.html)
- Place of Performance
- Address: 88th Medical Group/ MDSS/ SGSL/ TRBO, 4881 Sugar Maple Dr., Bldg 830, Wright-Patterson AFB,, Ohio, 45433, United States
- Zip Code: 45433
- Zip Code: 45433
- Record
- SN01956068-W 20090917/090916002640-f8b1096f34a6532e682e0fae50b47762 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |